摘要
Abstract
Objective:To explore the effects of blood transfusion therapy combined with mFOLFOX6 chemotherapy on the level of tumor markers and immune capacity in patients with colorectal cancer.Method:A total of 100 patients with colorectal cancer admitted to the Affiliated Cancer Hospital of Guizhou Medical University from July 2022 to July 2023 were selected as the study objects and divided into control group and observation group according to lottery method,with 50 cases in each group.The control group received mFOLFOX6 chemotherapy,while the observation group received blood transfusion therapy combined with mFOLFOX6 chemotherapy.The levels of tumor markers[alpha-fetoprtein(AFP),carbohydrate antigen 19-9(CA19-9),Thymidinekinase(TK1),Carcinoembryonic antigen(CEA)],immune capacity[mature T lymphocytes(CD3+),helper T cells(CD4+),cytotoxic T cells(CD8+)],clinical efficacy,quality of life and incidence of adverse reactions were compared.Result:After treatment,the levels of tumor markers in both groups decreased,and difference was not statistically significant(P>0.05).After treatment,the immune function indexes of all groups decreased,and the observation group was higher than the control group,and the difference was statistically significant(P<0.05).After treatment,the scores of quality of life in the observation group were higher than those in the control group,and the difference was statistically significant(P<0.05).After treatment,the incidence of adverse reactions in the observation group was lower than that in control group,and the difference was statistically significant(P<0.05).After treatment,the total clinical effective rate in obsrvation group was higher than that in control group,and the difference was statistically significant(P<0.05).Conclusion:mFOLFOX6 chemotherapy combined with blood transfusion can help reduce the level of tumor markers in patients with colorectal cancer,and the immune system of patients is not significantly affected,and the safety is high.关键词
输血治疗/mFOLFOX6化疗/结直肠癌/肿瘤标志物/机体免疫能力Key words
Blood transfusion therapy/mFOLFOX6 chemotherapy/Colorectal cancer/Tumor markers/Body immunity
